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Background. Elastase mediates important oxidative actions during the development of chronic obstructive pulmonary disease
(COPD). However, few resources for the inhibition of elastase have been investigated. Our study evaluated the ability of the
recombinant plant derived Bauhinia bauhinioidesKallikrein proteinase Inhibitor (rBbKI) to modulate elastase-induced pulmonary
inflammation. Methods. C57Bl/6 mice were given intratracheal elastase (ELA group) or saline (SAL group) and were treated
intraperitoneally with rBbKI (ELA-rBbKI and SAL-rBbKI groups). At day 28, the following analyses were performed: (I) lung
mechanics, (II) exhaled nitric oxide (ENO), (III) bronchoalveolar lavage fluid (BALF), and (IV) lung immunohistochemical
staining. Results. In addition to decreasing mechanical alterations and alveolar septum disruption, rBbKI reduced the number
of cells in the BALF and decreased the cellular expression of TNF-𝛼, MMP-9, MMP-12, TIMP-1, eNOS, and iNOS in airways and
alveolar walls compared with the ELA group. rBbKI decreased the volume proportion of 8-iso-PGF2𝛼, collagen, and elastic fibers in
the airways and alveolar walls comparedwith the ELA group. A reduction in the number ofMUC-5-positive cells in the airwaywalls
was also observed. Conclusion. rBbKI reduced elastase-induced pulmonary inflammation and extracellular matrix remodeling.
rBbKI may be a potential pharmacological tool for COPD treatment.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease characterized by chronic air-
flow limitation that is not fully reversible [1]. COPD patients
exhibit an abnormal inflammatory response to particles or
toxic gases causing several pathological changes in the lung
along with important comorbidities that can contribute to
disease severity [2].
The chronic pulmonary inflammatory process in COPD
is caused by smoking. It is important to emphasize that the
inflammatory response does not cease after smoking cessa-
tion [3].The inflammatory response in COPD results in large
and small airways becoming inflamed, goblet cell hyperplasia,
and an increase in mucosal glands [4]. The primary cells
involved in this process are neutrophils, macrophages, and
CD8+ lymphocytes in the upper airways, particularly in
advanced COPD [5].
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Lung tissue alterations in COPD are the result of an
imbalance between proteinases and antiproteinases. There is
evidence to support that the inhalation of cigarette smoke
induces an increase in neutrophils and macrophages which
release enzymes such as cathepsin B, K, L, and S, neutrophil
elastase, proteinase 3, and matrix metalloproteinases 9 and
12. These enzymes are not completely inhibited by antipro-
teinases, leading to the destruction of connective tissue [6, 7].
TheCOPD treatment approach is divided into the follow-
ing steps: reduction of risk factors, therapeutic management
of stable disease, and therapeutic management of disease
exacerbations [8]. Notably, no currently available treatment
reduces disease progression or suppresses inflammation in
small airways and lung parenchyma. To better study the
pathogenesis of emphysema, the elastase-induced animal
model was developed 30 years ago. It is a simple and widely
accepted emphysema animal model and is used to elucidate
the mechanisms involved in emphysema pathophysiology
and to examine new pharmacological approaches [4, 9].
Proteinase inhibitors inhibit proteolytic enzymes or
increase levels of endogenous antiproteinases and may con-
tribute to the prevention of disease progression [10]. Pro-
teinases are signaling molecules involved in hemostasis, cell
death, cell proliferation, DNA replication, the inflammatory
response, and tissue remodeling [11]. Protease inhibitors are
also present in plants and are involved in plant biological
functions and pathological conditions. Consequently, the
prevention of undesired proteolysis has been extensively
studied [12, 13].
Bauhinia is a plant genus from the subfamily Cae-
salpinioideae which comprises over 600 species native to
tropical and subtropical forests [14]. Numerous proteinase
inhibitors have been isolated from this genus, particularly
from the Bauhinia bauhinioides species. In the present study,
we evaluated the recombinant plant-derived the Bauhinia
bauhinioides kallikrein Inhibitor (rBbKI) [15].
Kallikreins are glycoproteins present in glandular cells,
neutrophils, and biological fluids. Human tissue kallikreins
are glycoproteins expressed in cells and tissues with specific
regulatory functions such as ion transport, glucose transport
in synergy with insulin, and regulation of blood flow through
the formation of kinins [13]. Elevated tissue levels of kinin
and kallikrein have been associated with hypertension and
diabetes [16].
BbKI, or its recombinant form rBbKI, inhibits trypsin,
plasmin, and chymotrypsin. This protein is also a potent
inhibitor of human plasma kallikrein (HuPk). Inhibition of
HuPK by BbKI/rBbKI causes a decrease in bradykinin release
due to the decreased availability of HuPK. BbKI is the first
plant-derived inhibitor of the primary structure set described
that is an inhibitor of tissue kallikrein [17, 18]. Indeed, rBbKI
was effective in inhibiting the viability of tumor cell lines [19].
The present study aimed to investigate whether
rBbKI contributes to the inactivation of elastase-induced
pulmonary mechanical alteration, inflammatory response,
extracellular matrix remodeling, and oxidative stress
responses.
2. Methods
2.1. Animals. Male C57Bl/6 mice (20–25 g) were maintained
in an animal facility with a 12-hour light-dark cycle and were
offered water and chow ad libitum. The animals received
humane care in compliance with the “Guide for Care and
Use of Laboratory Animals” (National Institutes of Health,
publication 86-23, revised 1985), and the study protocol was
approved by the Ethical Committee of the University of Sa˜o
Paulo.
2.2. Inhibitor Purification. Overexpression of the rBbKI in
E. coli BL21(DE3) cells and its purification were carried
according to Arau´jo et al. [15] modified by Zhou et al., [20].
Briefly, cells containing the target gene cloned into the expres-
sion vector pET28a (Novagen) were grown in Luria-Bertani
medium supplementedwith 30 g/mLkanamycin (Invitrogen)
at 37∘C to an optical density OD600 nm of 0.5, followed by
induction of the fusion-protein expression with isopropyl 𝛽-
D-thiogalactopyranoside (Invitrogen). IPTG was added at
a final concentration of 1mM and the culture was grown
for additional 3 h and centrifuged (4000×g, 20min, 4∘C)
(Hitachi Himac CR21-GIII). The pellets were resuspended in
10 mL of 0.05M Tris/HCl, pH 8.0 buffer, and 0.15M NaCl.
Bacterial cells disruption by sonication (Unique, Campinas,
Brazil) were lysed in 0.5% Triton X-114 (Sigma-Aldrich)
(twelve cycles of ultrasound, 30 s, 40W) and centrifuged
(4000×g, 20min, 4∘C). LPS was removed by addition of
chloroform (3 : 1, v/v) at 4∘C after centrifugation.The protein
was further purified byNi–NTA affinity chromatography and
eluted with an imidazole gradient (100–250mM) in the same
sonication buffer. The imidazole was removed by dialyzed
against 0.05M Tris/HCl, pH 8.0, and 0.15M NaCl buffer. The
His-tag was removed by digestion with 0.5U thrombin (GE
Healthcare) per milligram of fusion protein for 4 h at 18∘C.
The final step of purification involved molecular exclusion
chromatography on a Superdex 75 HR 10/30 column (A¨KTA
Purifier, GE Healthcare) in 0.05M Tris/HCl, pH 8.0, and
0.15M NaCl to separate the rBbKI protein from His-tag; the
homogeneity of the preparation was analyzed by SDS-PAGE
and on 𝜇-Bondapak C18 reverse phase column (Figure 1).
2.3. Elastase-Induced Emphysema Mice Model. Seven-week-
old C57Bl/6 mice were anesthetized via an intramuscular
injection of ketamine (400mg/kg) and xylazine (55mg/kg).
Each animal received an intratracheal instillation of 0.667UI
porcine pancreatic elastase (Elastase Type I/E-1250, Sigma
Aldrich) diluted in 50 𝜇L of sterile saline or 50 𝜇L of sterile
saline alone (control group) (Figure 2).
2.4. BbKI Treatment. After elastase instillation, the animals
received an intraperitoneal injection of rBbKI (2mg/kg) on
days 1, 15, and 21. All doses were administered two hours after
porcine pancreatic elastase instillation (Figure 2). This dose
was determined in the previous studies of Brito et al. [18]
which showed that this is the dose required to extrapolate
the amount necessary for complete inhibition of circulating
plasma kallikrein and no toxic effects was observed in the
experimental model.
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Figure 1: Reverse phase chromatograph, HPLC system 𝜇-Bondapak
C18. SDS-PAGE (15%) from reverse phase chromatography on C18.
(M) Molecular mass standards; (1) rBbKI (30𝜇g) treated with 𝛽-
mercaptoethanol.
Days
1 15 21 28
Lung mechanics, BALF, and tissue collection
Intraperitoneal injection of saline/rBbKI (0.2mL)
Intratracheal instillation of saline/elastase (50𝜇L)
and histopathological analysis
Figure 2: Timeline of the experimental protocol.
2.5. Experimental Design. Animals were divided into four
groups:
(a) Animals that received intratracheal instillation and an
intraperitoneal injection of saline (SAL, 𝑛 = 8).
(b) Animals that received intratracheal instillation of
elastase and an intraperitoneal injection of saline
(ELA, 𝑛 = 8).
(c) Animals that received intratracheal instillation of
saline and an intraperitoneal injection of rBbKI (SAL-
rBbKI, 𝑛 = 8).
(d) Animals that received intratracheal instillation of
elastase and an intraperitoneal injection of rBbKI
(ELA-rBbKI, 𝑛 = 8).
2.6. Mechanical Evaluation. Twenty-eight days after elastase
or saline instillation, mice were anesthetized using pentobar-
bital sodium (50mg/kg ip) and tracheostomized, and lung
mechanics were measured using a computer controlled small
animal ventilator (FlexiVent, Scireq, Montreal, Canada).
When the animal was motionless, data recording began.
We used a signal that produced oscillations at different
frequencies with the airflow material (0.25 to 19.625) for
16 seconds, maintaining a closed expiratory valve. Pressure
values were obtained and the impedance of the airway
(pressure/flow) was calculated as a function of the different
frequencies.
Using a pop-up signal of 75% in 16 seconds, 3 blocks
of 8 seconds were used to calculate the parameters of
the mechanical oscillation (i), according to the following
equation: 𝑍(𝑓) = 𝑅aw + 𝑖(2𝜋𝑓)𝑙aw + [𝐺tis − 𝑖𝐻tis]/(2𝜋𝑓)
𝛼.
In this model, 𝑍(𝑓) is the impedance of air as a function
of frequency, 𝑖 is the imaginary unit (−1.5), 𝑓 is frequency,
𝑙aw is the inertance of the airways, and 𝛼 = (2/𝜋) ∗
arctan(𝐻tis/𝐺tis). The parameters experimentally obtained
were airway resistance greater (𝑅aw), lower airway resistance
or tissue (𝐺tis), and lung tissue elastance (𝐻tis).
Animals were ventilated at 60 breaths/min with a tidal
volume of 20mL⋅kg−1. After these procedures, mice were
exsanguinated and a bronchoalveolar lavage fluid analysis
was performed. Afterward, the lungs were removed and
fixed at a constant pressure, 20 cmH
2
O, for 24 hours in 10%
formaldehyde.
2.7. Bronchoalveolar Lavage Fluid Analysis. Bronchoalveolar
lavage fluid (BALF) analysis was performed by injecting
0.5mL of saline three times through a tracheal cannula. Total
cell analysis was determined using a Neubauer chamber. Cell
differentiation was performed using a cytospin preparation
stained with Diff-Quick Reagent (Biochemical Sciences Inc.,
Swedesboro, NJ). A cell differential count was performed by
evaluating >250 cells using an optical microscope, using the
morphologic criteria [21].
2.8.Morphometric Studies. Histological sectionswere stained
with hematoxylin-eosin and were evaluated by researchers
blinded to the protocol design. The quantification of mean
linear intercept (Lm) was performed using an optical micro-
scope with an integrated eyepiece containing a known area
(104 𝜇m2 at a magnification of 1000x) of 50 lines and 100
points. We analyzed 20 randomly selected fields for each
animal.
To analyze elastic and collagen fibers, lung slices were
stained with picrosirius red, a specific method for collagen
detection, using the Weigert’s Resorcin-Fuchsin method for
elastic fibers.Wemeasured the total area of alveolar walls and
the area of collagen or elastic fibers in 15 to 20 microscopic
fields per lung using a 400x magnification and the Image-
ProPlus 4.5 Image Analysis System (Media Cybernetics, Sil-
ver Spring, USA). The collagen or elastic content (%) was
expressed as the relationship between the quantity of collagen
or elastic fibers in a specific frame and the total area of that
frame (volume fraction).
Additional slices were also prepared for immunohisto-
chemical staining to evaluate the expression of cellularMMP-
9, MMP-12, TIMP-1, MUC-5, iNOS, and eNOS.
Morphometric analysis was performed using an optical
microscope with a lattice of lines and points (50 lines and 100
points) using the point counting technique. We analyzed 20
fields of lung parenchyma. The results were expressed as the
% of positive area (volume fraction) [22, 23].
For airway evaluation, the reticle was coupled adjacent
to the wall of the airway from the base of the epithelium.
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Three to five airways were randomly selected for each animal
and approximately three fields per airway were evaluated.
This technique was used to count neutrophils, cells positive
for TNF-𝛼, MMP-9, MMP-12, TIMP-1, MUC-5, eNOS, and
iNOS, and the volume fraction of PGF2𝛼, collagen, and elastic
fibers [24].
2.9. Mean Linear Intercept (Lm). The alveolar diameter anal-
ysis was performed using a microscope with an appropriate
reticulum to calculate the mean alveolar diameter. The initial
area of alveolar walls was determined, excluding vessels and
airways.A latticewith 50 straight (100 points) lineswas placed
over the area of the alveolar walls and the intersections of
the points in the alveolar wall were counted. Thus, the mean
alveolar diameter was calculated according to the ratio of the
lung parenchyma area to the number of intersections between
the lines and the alveolar walls [21].
2.10. Immunohistochemistry. For immunohistochemistry
experiments, lung sections were deparaffinized and
rehydrated as follows: Step 1: recovery of antigen: sections
were treated with Proteinase K for 20 minutes (37∘C),
followed by 20 minutes at room temperature. The slides
were then washed in PBS. Step 2: blocking and incubation
with primary antibody: blocking of endogenous peroxidases
was performed by incubation with 3% hydrogen peroxide
(H
2
O
2
), 100V (3 × 10 minutes). This was followed by
incubation with primary antibodies which were applied to
sections of experimental and control tissue (positive and
negative) and the slides were incubated overnight. Step 3:
incubation with secondary antibody and peroxidase complex:
the slides were washed in PBS and incubated with the
secondary antibody using an ABCKit by Vectastain (Vector
Elite-PK-6105 (anti-goat)/PK-6101 (anti-rabbit)). Step 4:
visualization: the slides were washed in PBS and proteins
were visualized using 3,3󸀠-diaminobenzidine chromogen
(DAB) (Sigma Chemical Co., St. Louis, Missouri, USA).
Step 5: counter-staining and mounting of slides: the slides
were washed thoroughly in tap water and counter-stained
withHarris Hematoxylin (Merck, Darmstadt, Germany).The
slides were then washed in water, dehydrated, cleared, and
mounted using Entellan microscopy resin (Merck).
The following primary antibodies were used: anti-mouse
macrophage (MAC-2) (Cedarlane Lab, Ontario, Canada;
1 : 60,000); anti-mouse neutrophils (AbDSerotec, Kidlington,
UK; 1 : 400); anti-mouse matrix metalloproteinase (MMP) 9
(Santa Cruz Biotechnology, CA; 1 : 500); anti-mouseMMP-12
(Santa Cruz Biotechnology, CA; 1 : 100); anti-mouse inducible
nitric oxide synthase (iNOS) (LabVision, NeoMarkers, Cali-
fornia; 1 : 500); anti-endothelial nitric oxide synthase (eNOS)
(LabVision, NeoMarkers, CA; 1 : 100); anti-tissue inhibitor of
metalloproteinases (TIMP) 1 (LabVision, NeoMarkers, CA;
1 : 400); anti-tumor necrosis factor (TNF) 𝛼 (Santa Cruz
Biotechnology, California, U.S.; 1 : 100); anti-8-iso-PGF2𝛼
(Oxford Biomedical Research, Oxford, United Kingdom;
1 : 10.000), and anti-mucin (MUC) 5 (LabVision, NeoMark-
ers, CA; 1 : 400).
2.11. Data Analysis. Values are expressed as mean ± stan-
dard error (SEM). Statistical analysis was performed using
SigmaStat software (SPSS Inc., Chicago, IL, USA). Data were
evaluated using One-Way Analysis of Variance and multiple
comparisons were performed using the Holm-Sidakmethod.
A 𝑃 value < 0.05 was considered statistically significant.
3. Results
3.1. Lung Mechanics. Figure 3(a) shows the values of res-
piratory system elastance (𝐸rs) in all experimental groups.
There was a significant increase of 𝐸rs in ELA groups
when compared with controls (𝑃 < 0.05, SAL: 36.99
± 7.64 cmH
2
O⋅mL−1; ELA: 53.58 ± 15.36 cmH
2
O⋅mL−1⋅s;
SAL-rBbKI: 38.96 ± 4.58 cmH
2
O⋅mL−1; ELA-rBbKI: 36.83
± 5.7 cmH
2
O⋅mL−1). Additionally, there was a significant
difference between ELA and ELA-rBbKI animals (𝑃 < 0.05).
Figure 3(b) shows the values of respiratory system
resistance (𝑅rs) in all experimental groups. There
was a significant decrease of 𝑅rs in rBbKI groups
compared with the SAL group (𝑃 < 0.05, SAL: 1.06 ±
0.19 cmH
2
O/mL−1⋅s; ELA: 0.94 ± 0.24 cmH
2
O/mL−1⋅s;
SAL-rBbKI: 0.77 ± 0.09 cmH
2
O/mL−1⋅s; ELA-rBbKI: 0.84
± 0.18 cmH
2
O/mL−1⋅s). Animals that received elastase and
were treated with rBbKI demonstrated a decrease in 𝑅rs
compared with elastase-induced mice (𝑃 < 0.05).
Figure 3(c) shows the values of airway resistance (𝑅aw)
in all experimental groups. There was a significant increase
of 𝑅aw in ELA groups when compared with controls
(𝑃 < 0.05, SAL: 0.35 ± 0.22 cmH
2
O/mL/s; ELA: 0.66 ±
0.36 cmH
2
O/mL/s; SAL-rBbKI: 0.34 ± 0.04 cmH
2
O/mL/s;
ELA-rBbKI: 0.33 ± 0.04 cmH
2
O/mL/s). There was a signifi-
cant difference between the ELA and ELA-rBbKI groups (𝑃 <
0.05).
Figure 3(d) shows the values of lung tissue elastance (𝐻tis)
in all animals (SAL: 39.50 ± 6.89 cmH
2
O/mL/s(1−𝛼); ELA:
67.59 ± 28.18 cmH
2
O/mL/s(1−𝛼); SAL-rBbKI: 40.85 ± 6.19;
ELA-rBbKI: 37.36 ± 6.2 cmH
2
O/mL/s(1−𝛼)). Animals that
received elastase and were treated with rBbKI had decreased
𝐻tis compared with elastase-induced mice (𝑃 < 0.05).
Figure 3(e) shows the values of lung tissue damping
(𝐺tis) in all experimental groups. There was no difference
between both groups (SAL: 7.50 ± 0.76 cmH
2
O/mL/s(1−𝛼);
ELA: 8.56 ± 1.69 cmH
2
O/mL/s(1−𝛼); SAL-rBbKI:
7.25 ± 0.62 cmH
2
O/mL/s(1−𝛼); ELA-rBbKI: 8.86 ±
2.39 cmH
2
O/mL/s(1−𝛼)).
3.2. Bronchoalveolar Lavage Fluid. The total and differen-
tial inflammatory cell counts are shown in Table 1. The
ELA group had an increase in total inflammatory cells,
macrophages, neutrophils, lymphocytes, and eosinophils
compared with the SAL and SAL-rBbKI groups (𝑃 < 0.05).
Both cell counts were significantly reduced in the ELA-rBbKI
group compared with the ELA group (𝑃 < 0.05). There were
no significant differences between the SAL, SAL-rBbKI, and
ELA-rBbKI groups.
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Figure 3:Mechanical evaluation: respiratory system elastance (a), respiratory system resistance (b), airway resistance (c), lung tissue elastance
(d), and lung tissue damping (e) (∗𝑃 < 0.05 compared with SAL and SAL-rBbKI groups; ∗∗𝑃 < 0.05 compared with ELA-rBbKI group).
3.3. Mean Linear Intercept (Lm). Figure 4 shows the Lm
values in all experimental groups. There was a significant
increase of Lm in the ELA group compared with SAL and
SAL-rBbKI groups (𝑃 < 0.05). In the ELA-BbKI group we
observed a reduction of Lm compared with the ELA group
(𝑃 < 0.05). There were no significant differences between the
SAL, SAL-rBbKI, and ELA-rBbKI groups.
3.4. Lung Inflammation. Theabsolute values of inflammatory
markers in all experimental groups are shown in Table 2 for
alveolar walls and Table 3 for airways.
In the alveolar and airway walls, there was an increase in
neutrophils-positive cells in the ELA group compared with
controls (𝑃 < 0.05). rBbKI treatment reduced the number of
neutrophils-positive cells in the alveolar and airway walls in
6 Mediators of Inflammation
Table 1: Absolute values of amount of cells in bronchoalveolar lavage fluid (BALF). The total cells, macrophages, neutrophils, lymphocytes,
and eosinophils are expressed in 104 cells/mL. ∗𝑃 < 0.05, compared with the SAL and SAL-rBbKI groups; ∗∗𝑃 < 0.05, compared with the
ELA-rBbKI group.
Cells SAL ELA SAL-rBbKI ELA-rBbKI
Total cells (104 cells/mL) 0.79 ± 0.34 2.59 ± 0.99∗ 0.40 ± 0.09 0.67 ± 0.23∗∗
Macrophages (104 cells/mL) 0.78 ± 0.35 1.34 ± 0.53∗ 0.37 ± 0.66 0.45 ± 0.21∗∗
Neutrophils (104 cells/mL) 0.00 ± 0.00 0.87 ± 0.80∗ 0.02 ± 0.05 0.18 ± 0.16∗∗
Lymphocytes (104 cells/mL) 0.00 ± 0.00 0.32 ± 1.07∗ 0.00 ± 0.00 0.00 ± 0.00∗∗
Eosinophils (104 cells/mL) 0.00 ± 0.00 0.049 ± 0.028∗ 0.0019 ± 0.0018 0.01 ± 0.01∗∗
Table 2: Absolute values of the morphometric analysis for inflammatory, remodeling, and oxidative stress markers, in the alveolar walls. The
neutrophils, macrophages, TNF-𝛼, MMP-9, MMP-12, TIMP-1, iNOS, and eNOS are expressed in positive cells/104 𝜇m2. The collagen fiber,
elastic fiber, and 8-iso-PGF2𝛼 are expressed in percentage (%). ∗𝑃 < 0.05, compared with the SAL and SAL-rBbKI groups; ∗∗𝑃 < 0.05,
compared with the ELA-rBbKI group.
SAL ELA SAL-rBbKI ELA-rBbKI
Inflammatory markers
Neutrophils (cells/104 𝜇m2) 0.33 ± 0.07 1.35 ± 0.14∗ 0.55 ± 0.03 0.83 ± 0.78∗∗
Macrophages (cells/104 𝜇m2) 0.36 ± 0.03 1.19 ± 0.05∗ 0.68 ± 0.05 0.81 ± 0.41∗∗
TNF-𝛼 (cells/104 𝜇m2) 2.86 ± 0.54 12.50 ± 1.28∗ 4.85 ± 0.77 9.69 ± 0.91∗/∗∗
Remodeling markers
Collagen fibers (%) 9.64 ± 0.12 11.62 ± 0.83∗ 7.75 ± 0.91 10.30 ± 2.85∗∗
Elastic fibers (%) 0.29 ± 0.05 0.47 ± 0.08∗ 0.32 ± 0.10 0.30 ± 0.09∗∗
MMP-9 (cells/104 𝜇m2) 6.39 ± 0.79 17.92 ± 0.86∗ 7.90 ± 0.92 10, 82 ± 1.96∗∗
MMP-12 (cells/104 𝜇m2) 9.75 ± 0.92 21.46 ± 3.65∗ 7.88 ± 1.32 13.21 ± 1.51∗∗
TIMP-1 (cells/104 𝜇m2) 4.76 ± 0.53 13.58 ± 1.14∗ 5.95 ± 0.60 6.80 ± 1.08∗∗
Oxidative stress markers
iNOS (cells/104 𝜇m2) 4.52 ± 0.47 19.60 ± 2.75∗ 6.23 ± 1.24 9.82 ± 1.13∗/∗∗
eNOS (cells/104 𝜇m2) 4.13 ± 0.58 12.33 ± 1.87∗ 5.85 ± 0.78 7, 00 ± 1.05∗/∗∗
8-iso-PGF2𝛼 (%) 1.51 ± 0.64 17.94 ± 1.30∗ 1.48 ± 0.46 7.03 ± 1.25∗/∗∗
Table 3: Absolute values of the morphometric analysis for inflammatory, remodeling, and oxidative stress markers, in the airway walls. The
neutrophils, TNF-𝛼, MMP-9, MMP-12, TIMP-1, iNOS, eNOS, and MUC-5 are expressed in positive cells/104 𝜇m2. The collagen fiber, elastic
fiber, and 8-iso-PGF2𝛼 are expressed in percentage (%). ∗𝑃 < 0.05, compared with the SAL and SAL-rBbKI groups; ∗∗𝑃 < 0.05, compared
with the ELA-rBbKI group.
SAL ELA SAL-rBbKI ELA-rBbKI
Inflammatory markers
Neutrophils (cells/104 𝜇m2) 2.31 ± 0.27 4.23 ± 0.44∗ 2.20 ± 0.69 2.75 ± 0.46∗∗
TNF-𝛼 (cells/104 𝜇m2) 5.34 ± 0.34 15.38 ± 0.44∗ 6.90 ± 1.30 12.65 ± 0.538∗/∗∗
Remodeling markers
Collagen fibers (%) 5.95 ± 0.10 9.40 ± 0.82∗ 7.16 ± 0.69 8.64 ± 0.78∗∗
Elastic fibers (%) 0.45 ± 0.03 1.95 ± 0.08∗ 0.97 ± 0.06 1.23 ± 0.05∗∗
MMP-9 (cells/104 𝜇m2) 7.72 ± 0.87 16.57 ± 0.79∗ 6.63 ± 0.79 10.59 ± 1.04∗∗
MMP-12 (cells/104 𝜇m2) 13.45 ± 0.48 17.81 ± 1.00∗ 7.04 ± 1.07 11.77 ± 0.78∗∗
TIMP-1 (cells/104 𝜇m2) 4.34 ± 0.82 13.15 ± 1.15∗ 5.20 ± 0.79 6.72 ± 1.06∗∗
Oxidative stress markers
iNOS (cells/104 𝜇m2) 1.30 ± 0.61 5.62 ± 0.56∗ 1.16 ± 0.91 6.99 ± 0.61∗/∗∗
eNOS (cells/104 𝜇m2) 3.64 ± 0.57 12.22 ± 0.25∗ 1.74 ± 0.42 6.00 ± 0.32∗/∗∗
8-iso-PGF2𝛼 (%) 3.74 ± 0.79 23.47 ± 1.70∗ 3.78 ± 0.52 16.19 ± 1.07∗/∗∗
Mucus production
MUC-5 (cells/104 𝜇m2) 1.53 ± 0.26 7.66 ± 0.56∗ 1.32 ± 0.26 3.82 ± 0.41∗/∗∗
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Figure 4: Mean linear intercept (∗𝑃 < 0.05 compared with SAL and
SAL-rBbKI groups; ∗∗𝑃 < 0.05 compared with ELA-rBbKI group).
animals that received elastase (ELA-rBbKI group) compared
with the ELA group (𝑃 < 0.05). There were no significant
differences between the SAL, SAL-rBbKI, and ELA-rBbKI
groups.
In the alveolar walls, there was an increase in
macrophages-positive cells in the ELA group compared
with controls (𝑃 < 0.05). rBbKI treatment reduced the
number of macrophages-positive cells in the alveolar walls in
animals that received elastase (ELA-rBbKI group) compared
with the ELA group (𝑃 < 0.05). There were no significant
differences between the SAL, SAL-rBbKI, and ELA-rBbKI
groups.
In the alveolar and airway walls, there was an increase
in TNF-𝛼-positive cells in the ELA group compared with
controls (𝑃 < 0.05). rBbKI treatment reduced the number
of TNF-𝛼-positive cells in the alveolar and airway walls in
animals that received elastase (ELA-rBbKI group) compared
with the ELA group (𝑃 < 0.05), but there was an increase in
the ELA-rBbKI group compared with SAL and SAL-rBbKI
groups (𝑃 < 0.05). There were no significant differences
between the SAL and SAL-rBbKI groups.
3.5. Extracellular Matrix Remodeling. The absolute values of
remodeling markers in all experimental groups are shown in
Table 2 for alveolar walls and in Table 3 for airways.
In the alveolar walls, there was an increase in the volume
fraction of collagen fibers in the ELA group compared with
the SAL and SAL-rBbKI groups (𝑃 < 0.05). In the ELA-
rBbKI group, there was a reduction in the volume fraction
of collagen fibers compared with ELA group (𝑃 < 0.05).
Moreover, there was an increase in the volume fraction of
elastic fibers in the ELA group compared with the SAL and
SAL-rBbKI groups (𝑃 < 0.05). In the ELA-rBbKI group,
there was a reduction in the volume fraction of elastic fibers
compared with ELA group (𝑃 < 0.05). When evaluating
airway remodeling we obtained similar results; there was
an increase in the volume fraction of collagen and elastic
fibers in the ELA group compared with the SAL and SAL-
rBbKI groups (𝑃 < 0.05). rBbKI treatment in the ELA-rBbKI
group reduced the volume fraction of collagen and elastic
fibers compared with the ELA group (𝑃 < 0.05). There were
no significant differences between the SAL, SAL-rBbKI, and
ELA-rBbKI groups.
When evaluating the MMP-9, MMP-12, and TIMP-1
positive cells in the alveolar walls, we observed an increase
in MMP-9, MMP-12, and TIMP-1-positive cells in the ELA
group compared with the SAL, SAL-rBbKI, and ELA-rBbKI
groups (𝑃 < 0.05). rBbKI treatment in the ELA-rBbKI
group reduced the number ofMMP-9,MMP-12, and TIMP-1-
positive cells comparedwith the ELA group (𝑃 < 0.05).There
were no significant differences between the SAL, SAL-rBbKI,
and ELA-rBbKI groups.
We obtained similar results when evaluating the airways
walls.There was an increase in MMP-9, MMP-12, and TIMP-
1-positive cells in the ELA group compared with the SAL
and SAL-rBbKI groups (𝑃 < 0.05). rBbKI treatment in the
ELA-rBbKI group reduced the number of MMP-9, MMP-
12, and TIMP-1-positive cells compared with the ELA group
(𝑃 < 0.05). There were no significant differences between the
SAL, SAL-rBbKI, and ELA-rBbKI groups.
3.6. Oxidative Stress Response. The absolute values of oxida-
tive stress markers for all experimental groups are shown in
Table 2 for alveolar walls and Table 3 for the airways walls.
In the alveolar walls, there was an increase in iNOS and
eNOS-positive cells in the ELA group comparedwith the SAL
and SAL-rBbKI groups (𝑃 < 0.001). In the ELA-rBbKI group
we observed a reduction in the number of iNOS and eNOS-
positive cells compared with the ELA group (𝑃 < 0.05).
ELA-rBbKI group increase the number of iNOS and eNOS-
positive cells compared with the SAL and SAL-rBbKI groups
(𝑃 < 0.05). There were no significant differences between the
SAL and SAL-rBbKI groups.
We observed similar results in the airway walls; there
was an increase in iNOS and eNOS-positive cells in the ELA
group compared with the SAL and SAL-BbKI groups (𝑃 <
0.05). In the ELA-rBbKI group, there were a reduced number
of iNOS and eNOS-positive cells compared with the ELA
group (𝑃 < 0.001). ELA-rBbKI group increase the number
of iNOS and eNOS-positive cells compared with the SAL and
SAL-rBbKI groups (𝑃 < 0.05). There were no significant
differences between the SAL and SAL-rBbKI groups.
The evaluation of the volume fraction of 8-iso-PGF2𝛼
in alveolar and airways walls determined that there was an
increase of the volume fraction of 8-iso-PGF2𝛼 in the ELA
group compared with the SAL and SAL-rBbKI groups (𝑃 <
0.05). In the ELA-rBbKI group we observed a reduction of
the volume fraction of 8-iso-PGF2𝛼 compared with the ELA
group (𝑃 < 0.05). ELA-rBbKI group increase the number of
the volume fraction of 8-iso-PGF2𝛼 compared with the SAL
and SAL-rBbKI groups (𝑃 < 0.05). There were no significant
differences between the SAL and SAL-rBbKI groups.
3.7. Exhaled Nitric Oxide (ENO). Figure 5 shows the values of
exhaled nitric oxide (ENO) in all experimental groups.There
was a significant increase of ENO in the ELA group compared
with SAL and SAL-rBbKI groups (𝑃 < 0.05). rBbKI treatment
reduced ENO in the ELA-rBbKI group compared with ELA
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Figure 5: Exhaled nitric oxide (∗𝑃 < 0.05 compared with SAL and
SAL-rBbKI groups; ∗∗𝑃 < 0.05 compared with ELA-rBbKI group;
#
𝑃 < 0.05 compared with SAL group).
group (𝑃 < 0.05). There was a decrease of ENO in the SAL-
rBbKI group when compared with the SAL group (𝑃 < 0.05).
3.8. Mucin Cells in Airway Walls. The number of positive
MUC-5 cells was evaluated only in the airways and the
absolute values are shown in Table 2.
There was an increase in MUC-5-positive cells in the
airways in the ELA group compared with the SAL and SAL-
rBbKI groups (𝑃 < 0.5). In the ELA-rBbKI group we
observed a reduction in the number of MUC-5 positive cells
compared with ELA group (𝑃 < 0.05). ELA-rBbKI group
increase the number of MUC-5-positive cells in the airways
compared with the SAL and SAL-rBbKI groups (𝑃 < 0.05).
There were no significant differences between the SAL and
SAL-rBbKI groups.
3.9. Qualitative Analysis. Representative photomicrographs
are presented in Figure 6, illustrating the inflammatory,
remodeling, and oxidative stress processes in the alveolar
septa. The slides were stained for neutrophils and cells
expressingTNF-𝛼,MMP-9, TIMP-1, iNOS, and 8-iso-PGF2𝛼.
The ELA group exhibited increases in alveolar neutrophil
infiltration, the numbers of TNF-𝛼, MAC-2, MMP-9, MMP-
12, TIMP-1, eNOS, and iNOS-positive cells and the volume
fraction of the 8-iso-PGF2 𝛼, suggesting the presence of lung
inflammation, remodeling, and oxidative stress processes.
rBbKI treatment reduced the above changes in alveolar walls,
which can be observed in the representative photomicro-
graphs.
4. Discussion
We showed that rBbKI is able to attenuate the responses of
pulmonarymechanics, which has been associated with atten-
uation of inflammatory cells, extracellular cellular matrix
(ECM) remodeling, and TNF-𝛼-positive cells. There was a
significant reduction in the activation of the oxidative stress
pathway because we observed significant attenuation of the
number of iNOS and eNOS-positive cells and of the volume
fraction of 8-iso-PGF2𝛼 in the alveolar and airway wall in an
animal model of lung induced intratracheal elastase injury.
This model of chronic obstructive pulmonary disease
had been already studied in mice [21, 25]. In addition, these
previous studies showed the alveolar enlarge of lung tissue,
inflammation, and remodeling in mice treated with porcine
pancreatic elastase, constituting an interesting model for the
study of possible therapeutic strategies for emphysema [21,
26].
We found an effective decrease in alveolar enlargement
in the ELA-rBbKI group, after the porcine pancreatic elastase
instillation. Since Lm is a measurement of the average space
between opposing alveolar walls [27] and the emphysema
is characterized by alveolar wall destruction [1], the Lm
increase in ELA and ELA-rBbKI groups suggests emphysema
development in this experimental model and that the rBbKI
treatment decreased these parenchymal lesions.
Our results demonstrated that rBbKI treatment reduced
respiratory system resistance (𝑅rs), airway resistance (𝑅aw),
and elastance of the respiratory system (𝐸rs).
A bronchodilator effect caused by rBbKI treatment was
observed in the airways, which was demonstrated by the
reduction of respiratory system resistance (𝑅rs) in the rBbKI
treatment groups (Sal-rBbKI and ELA-rBbKI groups). This
observation was confirmed by the airway resistance (𝑅aw)
data, which declined in rBbKI-treated animals in the elastase
and saline groups. This suggests that rBbKI should be exam-
ined in future studies conducted in asthma experimental
models.
The increase in respiratory system elastance (𝐸rs) in
animals receiving intratracheal elastase is an acute effect of
elastase-induced lung injury. The 𝐸rs data are corroborated
by the 𝐻tis results, which exhibited the same response
pattern.These functional parameters demonstrated the effect
of rBbKI in the airway and alveolar walls. However, other
authors have observed different effects on lung mechanics in
elastase treated animal models.
Hantos et al. [28] examined mice that received an
intratracheal instillation of elastase and demonstrated a
volume increase and an elastance decrease in the lung tissue.
They observed no changes in airway resistance and tissue
resistance. These authors concluded that the destruction of
lung tissue was not associated with pulmonary mechanical
alterations.
Ito et al. [25] studied mice that received porcine pan-
creatic elastase by nebulization. They observed a decrease
in respiratory system elastance. The authors also suggested
that abnormal collagen remodeling is a major determinant of
pulmonary function and mechanical forces associated with
emphysema.
However, Scuri et al. [29] demonstrated that elastase
results in an increased production of bradykinin, leading to
increased resistance and elastance of the respiratory system.
The authors demonstrated that this responsewas not reversed
by treatment with a histamine antagonist but was effectively
blocked by a bradykinin B2 receptor antagonist, confirming
the involvement of the kallikrein-kinin system in the process.
In addition, another important aspect that suggests the
increase in the elastance and resistance of the lung tissue is
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Figure 6: Inflammatory cells, remodeling, and oxidative stress markers in the lung tissue. Magnification of 400x.
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the increase in the volume fraction of collagen and elastic
fibers in the ELA group. The elastic and collagen fibers
seem to be the major constituents of the extracellular matrix,
accounting for lung tissue viscoelastic mechanical properties,
and, interestingly, elastic fibers behave more linearly than
collagen fibers [25].
Chung and Adcock [30] suggested that the evaluation of
bronchoalveolar lavage fluid is one of the most common and
effective methods for monitoring lung inflammation.
In our study, we observed an increase in the number
of inflammatory cells in the elastase treated groups. These
results are likely due to the role of neutrophil elastase
displacement of leukocytes to the site of inflammation.There
were no significant differences in the number ofmacrophages
in bronchoalveolar lavage fluid from animals in the SAL and
SAL-rBbKI groups. There was a significant decrease in the
number of neutrophils, lymphocytes, and eosinophils in the
ELA-rBbKI group, indicating that rBbKI has an important
anti-inflammatory effect. These results were similar to that
reported byNeuhof et al. [31] in the lung edemamodel caused
by neutrophil activation; this study observed that an inhibitor
of the Kunitz family elastase BbCI decreased edema to the
same extent as a reference substance used for the treatment
of this disease. Suzuki et al. [32] observed that curcumin,
a member of the ginger family, significantly reduced the
number of macrophages, neutrophils, and total cells in the
BALF of mice that received intratracheal elastase.
Plantier et al. [33] evaluated the effect of growth ker-
atinocyte (KGF) treatment in rats given intratracheal elastase.
The authors demonstrated that KGF significantly decreased
the total cell number of macrophages and neutrophils in
bronchoalveolar lavage fluid. The results obtained with
inflammatory models using animals pretreated with a BbCI
inhibitor of HLE and cathepsin G and rBbKI inhibitors of
plasma kallikrein and human plasma kallikrein suggest the
involvement of proteinase inhibitors in the events of capture,
rolling, cell adhesion, and transmigration [15].
The numbers of neutrophils, macrophages, and TNF-𝛼-
positive cells were increased in the alveolar and airway walls
of the ELA group. rBbKI treatment decreased the numbers of
these cells in alveolar and airway walls.
Our assessment of extracellular matrix remodeling was
performed by evaluating collagen and elastic fibers in addi-
tion to metalloproteinase (MMP-9 and MMP-12) and TIMP-
1-positive cells in the alveolar and airway walls. rBbKI
treatment reduced the volume fraction of elastic fibers with
less attenuation of collagen fibers in alveolar and airwaywalls.
The study performed by Lopes et al. [34] demonstrated that
elastase-induced rats hadhigher elastin values comparedwith
animals that smoked for six months. The same pattern was
observed for Type I collagen, but the authors found no sig-
nificant differences between experimental groups. However,
the expression of Type III collagenwas higher in animals with
six months of smoke exposure compared with mice induced
by elastase.
rBbKI decreased the number of MMP-9- and MMP-12-
positive cells in the alveoli and airway walls. It has been
demonstrated that cathepsins can activate pro-urokinase,
which activates plasminogen to form plasmin, which in turn
activates metalloproteinases, primarily MMP-2 and MMP-
9. Plasmin also activates elastase, which increases metallo-
proteinase and cathepsin. rBbKI strongly inhibits the activity
of trypsin, plasmin, and HuPk (human plasma kallikrein).
The inhibition of human plasma kallikrein activity by rBbKI
causes a decreased release of bradykinin by decreasing the
availability of HuPK [18, 19].
The MMP-9 increase resulted in excess production of its
inhibitor, TIMP-1, as an attempt to repair the tissue damage.
An excess of TIMP-1 in animals may interfere with cellular
traffic and tissue repair andmay also contribute to an increase
of extracellular matrix deposition and fibrosis by inhibiting
MMP-9 [35].
We observed an increase in the number of MUC-5-
positive cells in animals receiving elastase, whichmay suggest
that it is a later development in disease progression. However,
mice, unlike humans, do not have true goblet cells, and
this should be taken into consideration [36]. In addition,
the washing steps during slide preparation may also have
contributed to the appearance of clear mucus in the airways.
Our results demonstrated that rRBbKI treatment reduced the
number of MUC-5-positive cells.
In the oxidative stress evaluation, we demonstrated that
the intratracheal elastase-induced pulmonary damage caused
an increase in exhaled nitric oxide (ENO), which has been
associated with increased numbers of macrophages, neu-
trophils, eosinophils, and lymphocytes.
Our rBbKI treatment group (ELA-rBbKI) had an atten-
uated oxidative stress response, with reduced expression of
eNOS and iNOS positive cells in both alveolar and airway
walls. There was a reduction in the volume fraction of 8-
iso-PGF2𝛼 in alveolar and airway walls. Considering the iso-
prostane response, it is known that contact between oxidizing
agents and the cell membrane results in lipid peroxidation
of the cell membrane, which is responsible for the formation
of a number of bioactive compounds known as isoprostanes,
which are similar to prostaglandins [37]. Isoprostanes possess
potent biological activity and are responsible for mediating
aspects of oxidative injury [38].
We previously observed that iNOS inhibition attenuated
hyperresponsiveness in animals with chronic allergic inflam-
mation [39]. These results may explain the changes in airway
resistance, because iNOS participates in airway modulation.
These effects appear to be related to the modulation of Rho-
kinase activity by iNOS [23, 24].
Consequently, the inflammatory response causes
increased proteinase production of bradykinin, increasing
the activation of proinflammatory cytokines and increasing
eNOS and iNOS.
The kallikrein-kinin system has been reported to be
important for vascular inflammatory responses (e.g., vasodi-
lation and vascular permeability). High expression of tissue
kallikrein protein has been reported to enhance tumorigen-
esis, cancer cell proliferation, angiogenesis, vascular perme-
ability, and regulation of cancer cell invasion in different can-
cers. rBbKI induces hyperpolarization of the endothelial cell
membrane and causes an increase in intracellular calcium.
It also significantly reduces proliferative activity, which is
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independent of rBbKI-induced hyperpolarization of the cell
membrane [40].
The present study had some limitations. In the current
study, an analysis of the toxicity of rBbKI was not performed,
but it emphasizes that this inhibitor was used in several
experimental models in vitro [40] and in vivo [18] and
also these authors did not identify adverse effects of the
use of this inhibitor. However, further studies are necessary
to assess toxicity. Our results support the importance of
rBbKI treatment in lung mechanics, lung inflammatory
responses, extracellular matrix remodeling, and oxidative
stress pathways. Additional studies are needed to elucidate
the mechanisms responsible for these changes.
5. Conclusions
We conclude that rBbKI treatment attenuated lung mechan-
ics, inflammatory recruitment, remodeling of the extracellu-
lar matrix, and oxidative stress responses in an experimental
lung injury model induced by intratracheal elastase admin-
istration. While further studies are required to explain the
biochemical mechanism, rBbKI is a promising therapeutic
strategy for the treatment of pulmonary emphysema.
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